CoMind

1/ @CoMind_ (CEO @jamesdacombe ) announces over $100M in funding Founded in 2018 by then 18-year old James Dacombe, CoMind has raised $102.5M in funding. The company’s most recent round of $60M was led by venture capital firm Plural, with participation from @localglobevc, Latitude, @OctopusVentures , Crane, and Angelini Ventures. The London-based health-tech startup is revolutionizing how clinicians monitor the brain. Their non-invasive device measures cerebral blood flow, intracranial pressure and cerebral autoregulation without puncturing the skull. The company will use the funds to advance regulatory approval in the U.S., complete further clinical trials and scale manufacturing. Read more: 🔗 eu-startups.com/2025/10/no-dri…

I’m hiring a Chief of Staff to work with me across @flux_computing and @CoMind_ to drive execution and alignment across both teams. We are scaling both companies rapidly - apply below. linkedin.com/jobs/view/4331…

1/ Very excited to share that @pluralplatform is leading a $60 million Series A in @CoMind_, the startup building breakthrough optical sensing technology to revolutionise brain monitoring and treatment.

We're excited to announce that CoMind has secured $102.5 million in funding to help us redefine how we monitor and treat the brain. For decades, doctors treating critically ill patients have been forced to compromise when monitoring the brain: use risky, expensive, highly invasive procedures that require drilling a hole into a patient's skull, or rely on inaccurate non-invasive monitoring that can compromise treatment decisions. Our technology resolves this dilemma for the first time. @CoMind_ One, is designed to non-invasively measure three physiological parameters simultaneously: cerebral blood flow, cerebral autoregulation, and intracranial pressure - something that has never been possible before at the patient bedside. Our latest round was led by Plural with participation from existing investors Angelini Ventures, LocalGlobe, Octopus Ventures, Crane, Backed VC and Entrepreneurs First. We will now be completing additional clinical trials, pursuing regulatory approval in the US, and expanding our team (we're hiring!). Plural partner @taavet will join CoMind's board alongside @svennj, General Partner at LocalGlobe, experienced healthcare executive Michael Tarnoff, MD, FACS and Chair of the Board Frank Fischer.

@CoMind_ is hiring! At CoMind we are working to redefine the way the brain is measured and treated to optimise patient outcomes across the care continuum. Our first product is a non-invasive neuromonitoring device, which will be used on patients in the ICU and surgery. In the future, we believe that we will non-invasively measure a large range of physiological signals, present these to clinicians and then use AI to predict future complications to provide personalised treatment plans for patients. Senior QARA Engineer (Software) - London Senior Software Engineer (C++) - London Embedded Software Engineer - London Software Test Engineer - London Senior Software Engineer (GUI) - London FPGA Engineer - London

What startups are building AI tools for analog design, PCB layout, EMC/SI analysis, etc? If no one’s doing this well, happy to seed a couple of people to build a demo and then trial it at CoMind and Flux.

Rob will also be participating in a Panel Discussion: Neurophotonics Industry and Relationships With Academia - 3:00 PM Sunday 26 Jan (PST) | Moscone South, Room 105 (Level 1 Lobby) We look forward to sharing our work and engaging in valuable discussions!

Monte Carlo simulations of time-of-flight resolved blood flow index: times-of-flight beyond 1 ns permit selective measurement of pulsatile cerebral blood flow Dominic Hill, Research Data Scientist 3:00 PM (PST) Tuesday 28 Jan | Moscone South, Room 213 (Level 2)

CoMind is excited to announce that after several years of advancing our unique optical neuromonitoring technology, we will be presenting our work for the first time at SPIE Photonics West in San Francisco this weekend (25th-30th). Please see below our talks and speakers:

We are thrilled to announce the appointment of Michael Tarnoff, MD to CoMind's Board of Directors. Mike is an incredibly experienced operator, previously served as CEO at @TuftsMedicalCtr in Boston, from 2020 to 2024, and has been a surgeon at Tufts since 2001, becoming Surgeon-in-Chief in 2019. His comprehensive background in clinical practice is complemented by significant leadership roles in the medical device industry; notably as Chief Medical Officer at @Medtronic from 2015 to August 2019. Prior to this, he served as Chief Medical Officer and Senior Vice President for Medical Affairs at Covidien from 2008, until its acquisition by Medtronic in 2015.

We're just 4 weeks away from #LSIEurope24, but the buzz is already building amongst leading #investors, #strategics, and #innovators for #LSIUSA25 in #DanaPoint, #California. After reviewing applications from global leaders working to build breakthrough #Medtech and #Healthtech businesses, we're revealing the first 100 Innovators selected to present at the event March 17th - 21st in 2025. Here's a sneak peek at 10 of them: Jamal Rushdy — #ArcuroMedical Jennifer Hoffmann — @biorithmhealth James Dacombe — @CoMind_ Danguole Altman — @CxPrecisionM Chris Barron — #EMBioSys Codi Gharagouzloo — #Imaginostics Yoonho Kim — #MagnendoCorp. Theadora James — #NavigateMaternity Chris Wood — #RevealDx Alex Jiao — @ScoutHealth Stay tuned for more innovator and investor announcements, and get in touch with our team to secure your spot at LSI USA '25. Our hotel room block at the Monarch Beach Resort is already nearing capacity, and is expected to sell out well in advance. Secure your spot today to ensure you get the best rate and secure a hotel room onsite before they’re sold out.

CoMind welcomes Marc to the team and is excited to start this journey with him.

he has advised some of the world's most successful medical device companies in the development of new products, and lectured all over the world. Marc brings a wealth of knowledge to the table in the development of the next generation of neurotechnologies with CoMind.

CoMind is thrilled to announce the addition of a new leader to the team: Marc Bloom as our Chief Medical Officer. Marc comes to us with an impressive background as the previous Chief of Neuroanaesthesiology and Professor at the University of Miami.

strategic direction of CoMind and our continued growth. CoMind welcomes Allie to the team and is excited to start this journey with her.

This makes her the perfect fit to lead CoMind's product strategy and product development roadmap. Allie will be responsible for defining CoMind's first product and building our future product portfolio to ensure market success, and will play an instrumental role in the